^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
BROCA Cancer Risk Panel

Type:
Laboratory Developed Test
Related tests:
Evidence

News

2years
Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. (PubMed, Breast Cancer Res Treat)
The high prevalence and heterogenous spectrum of pathogenic variants identified among self-reported African descendants in Northeast Brazil is consistent with studies in other African ancestry populations with a high burden of aggressive young onset breast cancer. It underscores the need to integrate comprehensive cancer risk assessment and genomic testing in the management of newly diagnosed Black women with breast cancer across the African Diaspora, enabling improved cancer control in admixed underserved and understudied populations.
Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCM (FA Complementation Group M) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
|
BROCA Cancer Risk Panel
over2years
BRCA1 D11q isoform expression impacts PARP inhibitor responses in ovarian carcinoma patient derived xenografts (LCC 2022)
PDX were treated with PARPi rucaparib (300-450mg/kg) and cisplatin (4mg/kg). Our work in PDX provides further evidence that BRCA1 D11q expression can impact on PARPi and platinum responses, and is a clinically relevant mechanism of PARPi resistance in a subset of patients with BRCA1 mutations. Whilst high D11q expression can be associated with secondary BRCA1 splice site mutations (PDX #049 and #217), it can arise independently (PDX #032). Thus, BRCA1 D11q isoform expression should be considered a potential mechanism of acquired PARPi-resistance in patients with BRCA1 exon 10 mutations.
Clinical • PARP Biomarker • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression
|
BROCA Cancer Risk Panel
|
cisplatin • Rubraca (rucaparib)
3years
[VIRTUAL] BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts (AACR 2021)
PDX were treated with PARPi rucaparib (300mg/kg) and cisplatin (4mg/kg). Our work in PDX provides additional functional evidence that BRCA1 D11q expression impacts on PARPi and platinum responses, and is a clinically relevant mechanism of PARPi resistance in a subset of patients with BRCA1 mutations. Whilst high D11q expression can be associated with secondary BRCA1 splice site mutations (PDX #1049), it can also occur in their absence (PDX #1032). Thus, BRCA1 D11q isoform expression should be considered a potential mechanism of PARP-resistance in patients with BRCA1 11q mutations.
Clinical • PARP Biomarker • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA1 expression
|
BROCA Cancer Risk Panel
|
cisplatin • Rubraca (rucaparib)
over4years
Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico. (PubMed, Sci Rep)
"This study reveals an unmet clinical need of genetic testing that could benefit a significant proportion of at-risk Latinas. It also highlights the complexity of Hispanic populations as pathogenic factors may originate from any of the ancestral populations that make up their genetic backgrounds."
Journal • Clinical
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • MUTYH (MutY homolog)
|
BROCA Cancer Risk Panel
almost6years
Inherited Breast Cancer in Nigerian Women. (PubMed, J Clin Oncol)
"Conclusion Among Nigerian women, one in eight cases of invasive breast cancer is a result of inherited mutations in BRCA1, BRCA2, PALB2, or TP53, and breast cancer risks associated with these genes are extremely high. Given limited resources, prevention and early detection services should be especially focused on these highest-risk women."
Journal • Clinical
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BROCA Cancer Risk Panel